J.P. Morgan has resumed coverage of 14 large-cap biotechnology firms, declaring that the industry appears to be entering a meaningful inflection point as wins in development increasingly convert into commercially viable and profitable businesses.
The bank pointed to a crop of companies that are either achieving sustained profitability or approaching it, supported by broader product lineups, deepening clinical pipelines and the prospect of business development activity to further diversify revenue sources.
In its note, J.P. Morgan assigned Overweight ratings to the following companies: Vertex Pharmaceuticals Inc (NASDAQ:VRTX), Alnylam Pharmaceuticals Inc (NASDAQ:ALNY), BeOne Medicines AG DRC (NASDAQ:ONC), United Therapeutics Corporation (NASDAQ:UTHR), Insmed Inc (NASDAQ:INSM), Ascendis Pharma AS (NASDAQ:ASND), Jazz Pharmaceuticals PLC (NASDAQ:JAZZ), Ionis Pharmaceuticals Inc (NASDAQ:IONS), Biomarin Pharmaceutical Inc (NASDAQ:BMRN) and Mirum Pharmaceuticals Inc (NASDAQ:MIRM).
The bank kept Neutral ratings on BioNTech SE (NASDAQ:BNTX), Incyte Corporation (NASDAQ:INCY) and Halozyme Therapeutics, and it initiated an Underweight rating on Moderna. J.P. Morgan emphasized different rationales for each stance, ranging from near-term commercial momentum to concerns around valuation and cash burn.
Analyst highlights and company-specific notes
- Vertex was described as a clear pivot story by J.P. Morgan, as the company expands beyond its cystic fibrosis franchise into areas such as kidney disease and pain management. The bank set a $515 price target.
- Alnylam received a $420 target, with analysts pointing to rapid growth of its Amvuttra franchise and signs of improving profitability.
- BeOne Medicines earned praise for continued momentum with Brukinsa and for demonstrating strong operating leverage.
- United Therapeutics was supported by confidence in Tyvaso adoption in idiopathic pulmonary fibrosis and potential upside for ralinepag in pulmonary arterial hypertension.
- Insmed was called a compelling opportunity after a sharp share pullback, with forecasted growth stemming from Brinsupri and the TPIP pipeline.
- Ascendis Pharma was noted for a strong launch of Yorvipath, which analysts expect will accelerate profitability quickly.
Risks and cautious views highlighted by the bank
J.P. Morgan cautioned on Moderna, arguing that the stock's recent rally already incorporates optimistic expectations for its cancer vaccine program while ongoing cash burn remains a structural concern. The bank also suggested that BioNTech lacks a near-term catalyst despite holding a large cash position and building an oncology pipeline.
More broadly, the note underlined that many of the firms in coverage are entering a phase characterized by improving margins, expanding therapeutic footprints and a steady cadence of clinical catalysts. These include several high-profile cardiovascular outcomes trials and oncology readouts expected later this year, which the bank identified as important upcoming events for the sector.